Project Grant R01CA296154
Award Date
8/1/25
Completion Date
5/31/30
Dollars Obligated
$658K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $269,280 to Cold Spring Harbor Laboratory to conduct research on a novel targeted approach for treating K-RAS(G12C) mutation-driven cancers. The research aims to develop prodrug molecules that can selectively degrade the K-RAS(G12C) oncogenic protein while simultaneously releasing cytotoxic natural products to target multiple cancer pathways. Key objectives include determining the...
This Project Grant award of $356,850 from the National Cancer Institute's Cancer Treatment Research Program (CFDA 93.395) supports a research project at the Medical College of Wisconsin to investigate the use of EGFR inhibitors in colorectal cancer patients with mutant RAS genes. The key objectives are to: 1) Conduct functional mechanistic studies to test RAS mutants and their ability to bind the NF1 tumor suppressor for EGFR inhibitor sensitivity; 2) Pharmacologically target wild-type RAS in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $435,827 to New York University School of Medicine to conduct research aimed at enhancing KRAS inhibitor therapy for cancer. The key objectives are to: 1) Evaluate four serine/threonine kinase family members as synthetic lethal targets and clarify the mechanistic basis for this synthetic lethality, and 2) Use CRISPR/Cas9 "mini-libraries" to define the synthetic...
The National Cancer Institute (NCI) awarded a $602,881 Project Grant under CFDA 93.395, the Cancer Treatment Research program, to Duke University. The grant supports research to develop novel immunotherapies using engineered IgG antibodies that can penetrate tumor cells and neutralize oncogenic mutations, such as KRAS. The research aims to translate these tumor cell-penetrating antibodies into the clinic, overcoming challenges associated with the low yield and half-life of previous recombinant...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $523,480.00 to the Dana-Farber Cancer Institute, Inc. to conduct research aimed at overcoming resistance to KRAS inhibitor therapies in pancreatic ductal adenocarcinoma (PDAC). The research will focus on defining how dysregulated iron metabolism and autophagy-dependent mechanisms contribute to both acute adaptive and long-term acquired resistance to KRAS inhibition in PDAC. The goal is to...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Johns Hopkins University to develop a mutant KRAS-targeted vaccine for the interception of pancreatic cancer development. The total award amount is $659,090 over the project period from September 1, 2024 to August 31, 2029. The key objectives are to evaluate the safety and immunogenicity of the mutant KRAS vaccine in individuals with genetic predisposition to pancreatic...
The National Cancer Institute (NCI) awarded a $162,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Cincinnati's Sponsored Research Services Division. The grant will fund research focused on "Targeting the HER Family in KRAS Mutant Colorectal Cancer." The research aims to determine the efficacy of co-targeting HER3 and KRAS in KRAS mutant colorectal cancer cell lines and patient-derived xenografts, as well as delineate the adaptive...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $636,046 to the Weill Medical College of Cornell University to conduct research aimed at defining the oncogenic potential and therapeutic dependencies of PDAC-associated KRAS variants. The key products and services to be delivered under this 5-year award, which began on November 25, 2024, include: Deciphering how cell lineage impacts the neoplastic transformation and molecular...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $433,256 to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. in Tampa, Florida. The funding supports research to identify novel targets and develop lead compounds to overcome resistance to KRAS inhibitors for lung, colon, and other cancers. The project leverages fragment-based chemoproteomics approaches to probe biological target...
This federal Project Grant award of $589,838.00 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Johns Hopkins University. The grant supports research to optimize an active mutant KRAS peptide vaccine for the treatment of colorectal cancer (CRC), which is the second leading cause of cancer-related mortality in the U.S. The research aims to develop improved methods for cancer treatment and increase cure rates for CRC patients....